rgbp. Sid... I am sure KOOS has Co's knocking at the door all the time! For BUYERS, this is the time where they might get a good deal, so now is the time to buy! But, KOOS has been keeping count of the potential buyers believe me? If there are quite a few, which is the probability IMO, he knows they will be back knocking at the door from time to time! As far as I can see, their offers have been very small! Co's know what we have, and want in, and that desire won't change as I see it?
Then, so many Co's that have bought other Co's made poor decisions for one reason or another, where the products went nowhere, so they are more careful with their buying habits now? They also have other products to work on, but not with the power and capability RGBP potentially has?
Then again, Apple, Microsoft, & others, have a long list of Co's that they bought out, and are now flooded with projects to pursue! And some may become obsolescent before they get around to putting them into production! So it is better to buy a Company that has products that can stand on their own feet, with little else to be done! They also realize that the more ready the Seller Co' is with a strong stable of proven products, the MUCH HIGHER the price will have to be, giving Koos the upper hand in negotiations!
Then if Koos was to sell early, Buyers might feel that too much has to be done, and that they might not be able to do as well as the sought after Co' would do? so once a certain threshold is met, those potential buyers will come out of the woodwork and pursue RGBP again!
If RGBP can place a solid number of ready to implement products on the table, that will look like Strawberry Short cake instead of a plain layer cake to them! They will have to pay dearly! So let's see what happens in the next 1-2 years where that slew of cancer immunology products will be proven clinically sound or just another product that turns out to be a bust! IMO The best to all..
All that might be a factor in keeping Koos's nose working hard on the grindstone!
Koos, knowing the
